- Home
- NRSN vs QNTM Comparison
NRSN vs QNTM Comparison
Compare NRSN & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRSN
- QNTM
- Stock Information
- Founded
- NRSN 2017
- QNTM 1998
- Country
- NRSN Israel
- QNTM Canada
- Employees
- NRSN N/A
- QNTM N/A
- Industry
- NRSN Biotechnology: Pharmaceutical Preparations
- QNTM
- Sector
- NRSN Health Care
- QNTM
- Exchange
- NRSN Nasdaq
- QNTM NYSE
- Market Cap
- NRSN 37.9M
- QNTM 35.6M
- IPO Year
- NRSN 2021
- QNTM N/A
- Fundamental
- Price
- NRSN $1.79
- QNTM $15.45
- Analyst Decision
- NRSN Buy
- QNTM
- Analyst Count
- NRSN 2
- QNTM 0
- Target Price
- NRSN $14.00
- QNTM N/A
- AVG Volume (30 Days)
- NRSN 297.9K
- QNTM 236.7K
- Earning Date
- NRSN 06-23-2025
- QNTM 05-14-2025
- Dividend Yield
- NRSN N/A
- QNTM N/A
- EPS Growth
- NRSN N/A
- QNTM N/A
- EPS
- NRSN N/A
- QNTM N/A
- Revenue
- NRSN N/A
- QNTM N/A
- Revenue This Year
- NRSN N/A
- QNTM N/A
- Revenue Next Year
- NRSN N/A
- QNTM N/A
- P/E Ratio
- NRSN N/A
- QNTM N/A
- Revenue Growth
- NRSN N/A
- QNTM N/A
- 52 Week Low
- NRSN $0.51
- QNTM $2.70
- 52 Week High
- NRSN $1.80
- QNTM $23.81
- Technical
- Relative Strength Index (RSI)
- NRSN 73.77
- QNTM 70.61
- Support Level
- NRSN $1.65
- QNTM $13.35
- Resistance Level
- NRSN $1.77
- QNTM $15.50
- Average True Range (ATR)
- NRSN 0.14
- QNTM 1.67
- MACD
- NRSN 0.02
- QNTM 0.23
- Stochastic Oscillator
- NRSN 100.00
- QNTM 96.46
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.